Compare OEC & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | TMCI |
|---|---|---|
| Founded | 1862 | 2014 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.8M | 292.0M |
| IPO Year | 2014 | 2021 |
| Metric | OEC | TMCI |
|---|---|---|
| Price | $3.84 | $4.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $6.25 | $6.17 |
| AVG Volume (30 Days) | ★ 476.0K | 305.4K |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,806,700,000.00 | $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $3.83 | $1.17 |
| 52 Week High | $8.64 | $5.44 |
| Indicator | OEC | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 27.23 | 49.75 |
| Support Level | N/A | $3.96 |
| Resistance Level | $6.06 | $4.88 |
| Average True Range (ATR) | 0.34 | 0.55 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 0.00 | 55.45 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.